nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—KIT—myenteric nerve plexus—rectum cancer	0.0401	0.0851	CbGeAlD
Ponatinib—PDGFRA—penis—rectum cancer	0.0284	0.0604	CbGeAlD
Ponatinib—RET—autonomic nervous system—rectum cancer	0.0281	0.0597	CbGeAlD
Ponatinib—FGFR4—renal system—rectum cancer	0.0119	0.0253	CbGeAlD
Ponatinib—FGFR4—female reproductive system—rectum cancer	0.00955	0.0203	CbGeAlD
Ponatinib—FGFR3—epithelium—rectum cancer	0.00877	0.0186	CbGeAlD
Ponatinib—BCR—seminal vesicle—rectum cancer	0.00874	0.0186	CbGeAlD
Ponatinib—FGFR3—renal system—rectum cancer	0.00814	0.0173	CbGeAlD
Ponatinib—FGFR3—urethra—rectum cancer	0.00799	0.017	CbGeAlD
Ponatinib—FGFR3—mammalian vulva—rectum cancer	0.00761	0.0162	CbGeAlD
Ponatinib—BCR—renal system—rectum cancer	0.00704	0.015	CbGeAlD
Ponatinib—BCR—urethra—rectum cancer	0.00691	0.0147	CbGeAlD
Ponatinib—BCR—mammalian vulva—rectum cancer	0.00658	0.014	CbGeAlD
Ponatinib—FGFR3—female reproductive system—rectum cancer	0.00652	0.0138	CbGeAlD
Ponatinib—FGFR1—urethra—rectum cancer	0.00615	0.0131	CbGeAlD
Ponatinib—RET—epithelium—rectum cancer	0.00604	0.0128	CbGeAlD
Ponatinib—FGFR1—mammalian vulva—rectum cancer	0.00586	0.0124	CbGeAlD
Ponatinib—FGFR2—epithelium—rectum cancer	0.00574	0.0122	CbGeAlD
Ponatinib—BCR—female reproductive system—rectum cancer	0.00564	0.012	CbGeAlD
Ponatinib—RET—renal system—rectum cancer	0.0056	0.0119	CbGeAlD
Ponatinib—FLT3—female reproductive system—rectum cancer	0.0056	0.0119	CbGeAlD
Ponatinib—FGFR4—lymph node—rectum cancer	0.00559	0.0119	CbGeAlD
Ponatinib—FGFR2—smooth muscle tissue—rectum cancer	0.00553	0.0118	CbGeAlD
Ponatinib—LCK—urethra—rectum cancer	0.00551	0.0117	CbGeAlD
Ponatinib—TEK—epithelium—rectum cancer	0.0055	0.0117	CbGeAlD
Ponatinib—FGFR2—renal system—rectum cancer	0.00533	0.0113	CbGeAlD
Ponatinib—TEK—smooth muscle tissue—rectum cancer	0.0053	0.0113	CbGeAlD
Ponatinib—LCK—mammalian vulva—rectum cancer	0.00524	0.0111	CbGeAlD
Ponatinib—KDR—seminal vesicle—rectum cancer	0.00518	0.011	CbGeAlD
Ponatinib—TEK—renal system—rectum cancer	0.00511	0.0108	CbGeAlD
Ponatinib—BCR—vagina—rectum cancer	0.0051	0.0108	CbGeAlD
Ponatinib—TEK—urethra—rectum cancer	0.00502	0.0107	CbGeAlD
Ponatinib—SRC—epithelium—rectum cancer	0.00489	0.0104	CbGeAlD
Ponatinib—PDGFRA—smooth muscle tissue—rectum cancer	0.0048	0.0102	CbGeAlD
Ponatinib—SRC—smooth muscle tissue—rectum cancer	0.00471	0.01	CbGeAlD
Ponatinib—PDGFRA—renal system—rectum cancer	0.00463	0.00983	CbGeAlD
Ponatinib—KIT—seminal vesicle—rectum cancer	0.00459	0.00975	CbGeAlD
Ponatinib—FGFR1—vagina—rectum cancer	0.00454	0.00964	CbGeAlD
Ponatinib—SRC—renal system—rectum cancer	0.00454	0.00964	CbGeAlD
Ponatinib—KDR—epithelium—rectum cancer	0.0045	0.00956	CbGeAlD
Ponatinib—KDR—smooth muscle tissue—rectum cancer	0.00433	0.00921	CbGeAlD
Ponatinib—FGFR2—female reproductive system—rectum cancer	0.00426	0.00906	CbGeAlD
Ponatinib—KDR—renal system—rectum cancer	0.00417	0.00886	CbGeAlD
Ponatinib—KDR—urethra—rectum cancer	0.0041	0.00871	CbGeAlD
Ponatinib—TEK—female reproductive system—rectum cancer	0.00409	0.00869	CbGeAlD
Ponatinib—LCK—vagina—rectum cancer	0.00406	0.00862	CbGeAlD
Ponatinib—ABL1—seminal vesicle—rectum cancer	0.00399	0.00849	CbGeAlD
Ponatinib—KIT—epithelium—rectum cancer	0.00399	0.00847	CbGeAlD
Ponatinib—KDR—mammalian vulva—rectum cancer	0.0039	0.00829	CbGeAlD
Ponatinib—KIT—smooth muscle tissue—rectum cancer	0.00384	0.00816	CbGeAlD
Ponatinib—PDGFRA—female reproductive system—rectum cancer	0.0037	0.00787	CbGeAlD
Ponatinib—KIT—renal system—rectum cancer	0.0037	0.00786	CbGeAlD
Ponatinib—SRC—female reproductive system—rectum cancer	0.00363	0.00772	CbGeAlD
Ponatinib—KIT—urethra—rectum cancer	0.00363	0.00772	CbGeAlD
Ponatinib—KIT—mammalian vulva—rectum cancer	0.00346	0.00735	CbGeAlD
Ponatinib—PDGFRA—vagina—rectum cancer	0.00335	0.00712	CbGeAlD
Ponatinib—ABL1—smooth muscle tissue—rectum cancer	0.00334	0.0071	CbGeAlD
Ponatinib—KDR—female reproductive system—rectum cancer	0.00334	0.0071	CbGeAlD
Ponatinib—BCR—lymph node—rectum cancer	0.0033	0.00701	CbGeAlD
Ponatinib—FLT3—lymph node—rectum cancer	0.00327	0.00696	CbGeAlD
Ponatinib—ABL1—renal system—rectum cancer	0.00322	0.00684	CbGeAlD
Ponatinib—ABL1—urethra—rectum cancer	0.00316	0.00672	CbGeAlD
Ponatinib—KDR—vagina—rectum cancer	0.00302	0.00642	CbGeAlD
Ponatinib—ABL1—mammalian vulva—rectum cancer	0.00301	0.0064	CbGeAlD
Ponatinib—KIT—female reproductive system—rectum cancer	0.00296	0.00629	CbGeAlD
Ponatinib—FGFR1—lymph node—rectum cancer	0.00293	0.00623	CbGeAlD
Ponatinib—KIT—vagina—rectum cancer	0.00268	0.00569	CbGeAlD
Ponatinib—RET—lymph node—rectum cancer	0.00263	0.00558	CbGeAlD
Ponatinib—LCK—lymph node—rectum cancer	0.00263	0.00558	CbGeAlD
Ponatinib—ABL1—female reproductive system—rectum cancer	0.00258	0.00548	CbGeAlD
Ponatinib—ABCG2—seminal vesicle—rectum cancer	0.00252	0.00535	CbGeAlD
Ponatinib—TEK—lymph node—rectum cancer	0.00239	0.00508	CbGeAlD
Ponatinib—ABL1—vagina—rectum cancer	0.00233	0.00495	CbGeAlD
Ponatinib—PDGFRA—lymph node—rectum cancer	0.00217	0.0046	CbGeAlD
Ponatinib—SRC—lymph node—rectum cancer	0.00213	0.00451	CbGeAlD
Ponatinib—CYP2C8—renal system—rectum cancer	0.00209	0.00444	CbGeAlD
Ponatinib—ABCG2—urethra—rectum cancer	0.00199	0.00424	CbGeAlD
Ponatinib—KDR—lymph node—rectum cancer	0.00195	0.00415	CbGeAlD
Ponatinib—ABCG2—mammalian vulva—rectum cancer	0.0019	0.00403	CbGeAlD
Ponatinib—CYP3A5—renal system—rectum cancer	0.00188	0.004	CbGeAlD
Ponatinib—KIT—lymph node—rectum cancer	0.00173	0.00368	CbGeAlD
Ponatinib—CYP2C8—female reproductive system—rectum cancer	0.00167	0.00355	CbGeAlD
Ponatinib—CYP2C8—vagina—rectum cancer	0.00151	0.00321	CbGeAlD
Ponatinib—ABL1—lymph node—rectum cancer	0.00151	0.0032	CbGeAlD
Ponatinib—ABCG2—vagina—rectum cancer	0.00147	0.00312	CbGeAlD
Ponatinib—CYP3A4—renal system—rectum cancer	0.00141	0.003	CbGeAlD
Ponatinib—CYP2D6—renal system—rectum cancer	0.00139	0.00296	CbGeAlD
Ponatinib—CYP3A5—vagina—rectum cancer	0.00136	0.0029	CbGeAlD
Ponatinib—ABCB1—seminal vesicle—rectum cancer	0.00124	0.00264	CbGeAlD
Ponatinib—CYP3A4—female reproductive system—rectum cancer	0.00113	0.00241	CbGeAlD
Ponatinib—CYP2D6—female reproductive system—rectum cancer	0.00111	0.00237	CbGeAlD
Ponatinib—ABCB1—epithelium—rectum cancer	0.00108	0.00229	CbGeAlD
Ponatinib—ABCB1—renal system—rectum cancer	0.001	0.00213	CbGeAlD
Ponatinib—ABCB1—urethra—rectum cancer	0.000983	0.00209	CbGeAlD
Ponatinib—ABCG2—lymph node—rectum cancer	0.000951	0.00202	CbGeAlD
Ponatinib—ABCB1—mammalian vulva—rectum cancer	0.000936	0.00199	CbGeAlD
Ponatinib—ABCB1—female reproductive system—rectum cancer	0.000802	0.0017	CbGeAlD
Ponatinib—ABCB1—vagina—rectum cancer	0.000725	0.00154	CbGeAlD
Ponatinib—ABCB1—lymph node—rectum cancer	0.000469	0.000996	CbGeAlD
Ponatinib—FGFR4—Adaptive Immune System—HRAS—rectum cancer	0.000205	0.000388	CbGpPWpGaD
Ponatinib—LCK—B Cell Activation—KRAS—rectum cancer	0.000205	0.000387	CbGpPWpGaD
Ponatinib—LCK—Downstream signal transduction—HRAS—rectum cancer	0.000203	0.000384	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR—HRAS—rectum cancer	0.000202	0.000382	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—NRAS—rectum cancer	0.000202	0.000381	CbGpPWpGaD
Ponatinib—LCK—Signaling by ERBB2—HRAS—rectum cancer	0.000201	0.00038	CbGpPWpGaD
Ponatinib—LCK—DAP12 signaling—HRAS—rectum cancer	0.0002	0.000378	CbGpPWpGaD
Ponatinib—SRC—Signaling by SCF-KIT—HRAS—rectum cancer	0.0002	0.000378	CbGpPWpGaD
Ponatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000197	0.000373	CbGpPWpGaD
Ponatinib—SRC—BDNF signaling pathway—HRAS—rectum cancer	0.000197	0.000371	CbGpPWpGaD
Ponatinib—LCK—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.000196	0.000371	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR in disease—KRAS—rectum cancer	0.000196	0.00037	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR—KRAS—rectum cancer	0.000194	0.000367	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—NRAS—rectum cancer	0.000194	0.000366	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—NRAS—rectum cancer	0.000193	0.000364	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR in Cancer—KRAS—rectum cancer	0.000193	0.000364	CbGpPWpGaD
Ponatinib—BCR—Disease—KRAS—rectum cancer	0.000192	0.000363	CbGpPWpGaD
Ponatinib—SRC—Signaling by PDGF—KRAS—rectum cancer	0.000192	0.000362	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by NGF—HRAS—rectum cancer	0.000191	0.000361	CbGpPWpGaD
Ponatinib—FGFR1—Axon guidance—KRAS—rectum cancer	0.000189	0.000358	CbGpPWpGaD
Ponatinib—LCK—DAP12 interactions—HRAS—rectum cancer	0.000188	0.000356	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR in disease—HRAS—rectum cancer	0.000188	0.000356	CbGpPWpGaD
Ponatinib—LCK—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000188	0.000356	CbGpPWpGaD
Ponatinib—KIT—Signaling by NGF—HRAS—rectum cancer	0.000187	0.000354	CbGpPWpGaD
Ponatinib—LYN—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000187	0.000354	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR—HRAS—rectum cancer	0.000187	0.000353	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—KRAS—rectum cancer	0.000186	0.000352	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.000185	0.000349	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.000185	0.000349	CbGpPWpGaD
Ponatinib—LCK—Signaling by PDGF—HRAS—rectum cancer	0.000184	0.000348	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—KRAS—rectum cancer	0.000184	0.000347	CbGpPWpGaD
Ponatinib—SRC—Downstream signal transduction—HRAS—rectum cancer	0.00018	0.00034	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR—HRAS—rectum cancer	0.000179	0.000338	CbGpPWpGaD
Ponatinib—SRC—EGF/EGFR Signaling Pathway—HRAS—rectum cancer	0.000179	0.000338	CbGpPWpGaD
Ponatinib—FGFR3—Adaptive Immune System—KRAS—rectum cancer	0.000179	0.000338	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.000178	0.000337	CbGpPWpGaD
Ponatinib—SRC—Signaling by ERBB2—HRAS—rectum cancer	0.000178	0.000336	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by NGF—HRAS—rectum cancer	0.000178	0.000336	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by NGF—HRAS—rectum cancer	0.000177	0.000335	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—NRAS—rectum cancer	0.000175	0.000331	CbGpPWpGaD
Ponatinib—LCK—B Cell Activation—HRAS—rectum cancer	0.000174	0.000329	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.000174	0.000328	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—NRAS—rectum cancer	0.00017	0.000322	CbGpPWpGaD
Ponatinib—LCK—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000167	0.000315	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR in disease—HRAS—rectum cancer	0.000167	0.000315	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—KRAS—rectum cancer	0.000167	0.000315	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—KRAS—rectum cancer	0.000166	0.000313	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR—HRAS—rectum cancer	0.000165	0.000312	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000164	0.00031	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.000164	0.000309	CbGpPWpGaD
Ponatinib—BCR—Disease—HRAS—rectum cancer	0.000163	0.000308	CbGpPWpGaD
Ponatinib—SRC—Signaling by PDGF—HRAS—rectum cancer	0.000163	0.000308	CbGpPWpGaD
Ponatinib—FGFR1—Axon guidance—HRAS—rectum cancer	0.000161	0.000304	CbGpPWpGaD
Ponatinib—LYN—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.000159	0.000301	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—HRAS—rectum cancer	0.000158	0.000299	CbGpPWpGaD
Ponatinib—SRC—Focal Adhesion—HRAS—rectum cancer	0.000157	0.000298	CbGpPWpGaD
Ponatinib—FGFR4—Disease—NRAS—rectum cancer	0.000157	0.000297	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—NRAS—rectum cancer	0.000157	0.000297	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—NRAS—rectum cancer	0.000156	0.000295	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—HRAS—rectum cancer	0.000156	0.000295	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—NRAS—rectum cancer	0.000155	0.000293	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000153	0.00029	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—TYMS—rectum cancer	0.000152	0.000288	CbGpPWpGaD
Ponatinib—FGFR3—Adaptive Immune System—HRAS—rectum cancer	0.000152	0.000287	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—KRAS—rectum cancer	0.000151	0.000285	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—NRAS—rectum cancer	0.000149	0.000281	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000148	0.000279	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—KRAS—rectum cancer	0.000147	0.000277	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—NRAS—rectum cancer	0.000146	0.000276	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—NRAS—rectum cancer	0.000143	0.00027	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—HRAS—rectum cancer	0.000142	0.000268	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—HRAS—rectum cancer	0.000141	0.000266	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—NRAS—rectum cancer	0.00014	0.000265	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—NRAS—rectum cancer	0.00014	0.000265	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—NRAS—rectum cancer	0.000139	0.000262	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—NRAS—rectum cancer	0.000138	0.000261	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—NRAS—rectum cancer	0.000138	0.000261	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—NRAS—rectum cancer	0.000137	0.00026	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—NRAS—rectum cancer	0.000136	0.000256	CbGpPWpGaD
Ponatinib—FGFR4—Disease—KRAS—rectum cancer	0.000135	0.000256	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—KRAS—rectum cancer	0.000135	0.000255	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—NRAS—rectum cancer	0.000135	0.000255	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—KRAS—rectum cancer	0.000135	0.000254	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—KRAS—rectum cancer	0.000134	0.000252	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—NRAS—rectum cancer	0.000133	0.000252	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—NRAS—rectum cancer	0.000133	0.000251	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.00013	0.000246	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—HRAS—rectum cancer	0.000128	0.000242	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—KRAS—rectum cancer	0.000128	0.000242	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—NRAS—rectum cancer	0.000126	0.000238	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—KRAS—rectum cancer	0.000126	0.000238	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—HRAS—rectum cancer	0.000125	0.000235	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—KRAS—rectum cancer	0.000123	0.000232	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—NRAS—rectum cancer	0.000122	0.00023	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—NRAS—rectum cancer	0.000121	0.000229	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—KRAS—rectum cancer	0.000121	0.000228	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—KRAS—rectum cancer	0.000121	0.000228	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TP53—rectum cancer	0.00012	0.000226	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—KRAS—rectum cancer	0.000119	0.000225	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—KRAS—rectum cancer	0.000119	0.000225	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—KRAS—rectum cancer	0.000119	0.000225	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—KRAS—rectum cancer	0.000118	0.000224	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—NRAS—rectum cancer	0.000117	0.000221	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—KRAS—rectum cancer	0.000117	0.00022	CbGpPWpGaD
Ponatinib—FGFR3—Disease—NRAS—rectum cancer	0.000116	0.00022	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—KRAS—rectum cancer	0.000116	0.000219	CbGpPWpGaD
Ponatinib—FGFR4—Disease—HRAS—rectum cancer	0.000115	0.000217	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—HRAS—rectum cancer	0.000115	0.000217	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—KRAS—rectum cancer	0.000115	0.000217	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—HRAS—rectum cancer	0.000114	0.000216	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—KRAS—rectum cancer	0.000114	0.000216	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—HRAS—rectum cancer	0.000114	0.000215	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—NRAS—rectum cancer	0.000111	0.00021	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—NRAS—rectum cancer	0.00011	0.000208	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.000109	0.000206	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—HRAS—rectum cancer	0.000109	0.000206	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—KRAS—rectum cancer	0.000108	0.000205	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—HRAS—rectum cancer	0.000107	0.000202	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—KRAS—rectum cancer	0.000105	0.000198	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—HRAS—rectum cancer	0.000105	0.000197	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—KRAS—rectum cancer	0.000105	0.000197	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—rectum cancer	0.000104	0.000196	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—rectum cancer	0.000103	0.000195	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—HRAS—rectum cancer	0.000103	0.000194	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—HRAS—rectum cancer	0.000103	0.000194	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—HRAS—rectum cancer	0.000101	0.000192	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—HRAS—rectum cancer	0.000101	0.000191	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—HRAS—rectum cancer	0.000101	0.000191	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—KRAS—rectum cancer	0.000101	0.00019	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—TYMS—rectum cancer	0.000101	0.00019	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—HRAS—rectum cancer	0.000101	0.00019	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—NRAS—rectum cancer	0.0001	0.000189	CbGpPWpGaD
Ponatinib—FGFR3—Disease—KRAS—rectum cancer	0.0001	0.000189	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—NRAS—rectum cancer	0.0001	0.000189	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—HRAS—rectum cancer	9.91e-05	0.000187	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—HRAS—rectum cancer	9.87e-05	0.000186	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—NRAS—rectum cancer	9.83e-05	0.000186	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—HRAS—rectum cancer	9.74e-05	0.000184	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—HRAS—rectum cancer	9.72e-05	0.000184	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	9.7e-05	0.000183	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—NRAS—rectum cancer	9.6e-05	0.000181	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—KRAS—rectum cancer	9.56e-05	0.000181	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—KRAS—rectum cancer	9.48e-05	0.000179	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—HRAS—rectum cancer	9.22e-05	0.000174	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—HRAS—rectum cancer	8.93e-05	0.000169	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—HRAS—rectum cancer	8.88e-05	0.000168	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—NRAS—rectum cancer	8.85e-05	0.000167	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—NRAS—rectum cancer	8.67e-05	0.000164	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—KRAS—rectum cancer	8.63e-05	0.000163	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—KRAS—rectum cancer	8.61e-05	0.000163	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HRAS—rectum cancer	8.57e-05	0.000162	CbGpPWpGaD
Ponatinib—KIT—Immune System—NRAS—rectum cancer	8.51e-05	0.000161	CbGpPWpGaD
Ponatinib—FGFR3—Disease—HRAS—rectum cancer	8.51e-05	0.000161	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—NRAS—rectum cancer	8.5e-05	0.000161	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—rectum cancer	8.5e-05	0.000161	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—KRAS—rectum cancer	8.46e-05	0.00016	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—rectum cancer	8.42e-05	0.000159	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—KRAS—rectum cancer	8.26e-05	0.000156	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—NRAS—rectum cancer	8.15e-05	0.000154	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—HRAS—rectum cancer	8.13e-05	0.000154	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—NRAS—rectum cancer	8.08e-05	0.000153	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—HRAS—rectum cancer	8.06e-05	0.000152	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—NRAS—rectum cancer	8.06e-05	0.000152	CbGpPWpGaD
Ponatinib—FGFR2—Disease—NRAS—rectum cancer	8e-05	0.000151	CbGpPWpGaD
Ponatinib—KIT—Disease—NRAS—rectum cancer	7.86e-05	0.000148	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KRAS—rectum cancer	7.62e-05	0.000144	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—rectum cancer	7.52e-05	0.000142	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KRAS—rectum cancer	7.46e-05	0.000141	CbGpPWpGaD
Ponatinib—FGFR1—Disease—NRAS—rectum cancer	7.46e-05	0.000141	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—NRAS—rectum cancer	7.44e-05	0.000141	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—HRAS—rectum cancer	7.33e-05	0.000139	CbGpPWpGaD
Ponatinib—KIT—Immune System—KRAS—rectum cancer	7.32e-05	0.000138	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KRAS—rectum cancer	7.32e-05	0.000138	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—HRAS—rectum cancer	7.32e-05	0.000138	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—TYMS—rectum cancer	7.21e-05	0.000136	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—HRAS—rectum cancer	7.19e-05	0.000136	CbGpPWpGaD
Ponatinib—LYN—Immune System—NRAS—rectum cancer	7.11e-05	0.000134	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NRAS—rectum cancer	7.1e-05	0.000134	CbGpPWpGaD
Ponatinib—ABL1—Immune System—NRAS—rectum cancer	7.07e-05	0.000134	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HRAS—rectum cancer	7.02e-05	0.000133	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KRAS—rectum cancer	7.01e-05	0.000132	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KRAS—rectum cancer	6.95e-05	0.000131	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KRAS—rectum cancer	6.93e-05	0.000131	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KRAS—rectum cancer	6.89e-05	0.00013	CbGpPWpGaD
Ponatinib—KIT—Disease—KRAS—rectum cancer	6.76e-05	0.000128	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—rectum cancer	6.48e-05	0.000122	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KRAS—rectum cancer	6.42e-05	0.000121	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KRAS—rectum cancer	6.4e-05	0.000121	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—rectum cancer	6.34e-05	0.00012	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TYMS—rectum cancer	6.24e-05	0.000118	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—rectum cancer	6.23e-05	0.000118	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—rectum cancer	6.23e-05	0.000118	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—rectum cancer	6.22e-05	0.000117	CbGpPWpGaD
Ponatinib—LYN—Immune System—KRAS—rectum cancer	6.12e-05	0.000116	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KRAS—rectum cancer	6.11e-05	0.000115	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KRAS—rectum cancer	6.09e-05	0.000115	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—rectum cancer	5.96e-05	0.000113	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—rectum cancer	5.91e-05	0.000112	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—rectum cancer	5.89e-05	0.000111	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—rectum cancer	5.85e-05	0.000111	CbGpPWpGaD
Ponatinib—LCK—Immune System—NRAS—rectum cancer	5.82e-05	0.00011	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—rectum cancer	5.75e-05	0.000109	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NRAS—rectum cancer	5.6e-05	0.000106	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NRAS—rectum cancer	5.5e-05	0.000104	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—rectum cancer	5.46e-05	0.000103	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—rectum cancer	5.44e-05	0.000103	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TYMS—rectum cancer	5.44e-05	0.000103	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—rectum cancer	5.43e-05	0.000103	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—rectum cancer	5.38e-05	0.000102	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—rectum cancer	5.22e-05	9.87e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—rectum cancer	5.21e-05	9.84e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—rectum cancer	5.2e-05	9.82e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—rectum cancer	5.19e-05	9.81e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—rectum cancer	5.17e-05	9.78e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—rectum cancer	5.16e-05	9.74e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TYMS—rectum cancer	5.13e-05	9.68e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—rectum cancer	5.01e-05	9.47e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—rectum cancer	4.82e-05	9.11e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—rectum cancer	4.76e-05	8.99e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—rectum cancer	4.74e-05	8.95e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—rectum cancer	4.63e-05	8.74e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—rectum cancer	4.59e-05	8.68e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—rectum cancer	4.49e-05	8.49e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—rectum cancer	4.48e-05	8.47e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—rectum cancer	4.44e-05	8.38e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—rectum cancer	4.29e-05	8.1e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—rectum cancer	4.26e-05	8.05e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—rectum cancer	4.21e-05	7.95e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—rectum cancer	4.1e-05	7.74e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—rectum cancer	4.1e-05	7.74e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—rectum cancer	4.03e-05	7.6e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—rectum cancer	3.99e-05	7.55e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—rectum cancer	3.98e-05	7.53e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—rectum cancer	3.95e-05	7.47e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—rectum cancer	3.93e-05	7.43e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—rectum cancer	3.82e-05	7.22e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—rectum cancer	3.81e-05	7.2e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—rectum cancer	3.77e-05	7.13e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—rectum cancer	3.77e-05	7.11e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—rectum cancer	3.51e-05	6.64e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—rectum cancer	3.48e-05	6.58e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—rectum cancer	3.36e-05	6.35e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMS—rectum cancer	3.35e-05	6.33e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—rectum cancer	3.33e-05	6.3e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—rectum cancer	3.24e-05	6.12e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—rectum cancer	2.88e-05	5.44e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—rectum cancer	2.87e-05	5.42e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—rectum cancer	2.75e-05	5.2e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—rectum cancer	2.55e-05	4.82e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—rectum cancer	2.44e-05	4.61e-05	CbGpPWpGaD
